Piclozotan

Piclozotan
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]-1,4-benzoxazepin-5(4H)-one;
CAS Number	182415-09-4 ;
PubChem CID	9801640;
ChemSpider	7977402 ;
UNII	FQE44HS7AH;
Chemical and physical data
Formula	C23H24ClN3O2
Molar mass	409.909 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CC=C1C2=CC=CC=N2)CCCCN3C(=COC4=CC=CC=C4C3=O)Cl;
	InChI InChI=1S/C23H24ClN3O2/c24-22-17-29-21-9-2-1-7-19(21)23(28)27(22)14-6-5-13-26-15-10-18(11-16-26)20-8-3-4-12-25-20/h1-4,7-10,12,17H,5-6,11,13-16H2 ; Key:URMTUEWUIGOJBW-UHFFFAOYSA-N ;
(what is this?) (verify)

Piclozotan (SUN-N4057) is a selective 5-HT_1A receptor partial agonist, which has neuroprotective effects in animal studies.[1] It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced.[2][3]

References

Kamei, K.; Maeda, N.; Nomura, K.; Shibata, M.; Katsuragi-Ogino, R.; Koyama, M.; Nakajima, M.; Inoue, T.; Ohno, T.; Tatsuoka, T. (2006). "Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan". Bioorganic & Medicinal Chemistry. 14 (6): 1978–1992. doi:10.1016/j.bmc.2005.10.046. PMID 16290165.
Ferro, J.; Dávalos, A. (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular diseases (Basel, Switzerland). 21 Suppl 2 (2): 127–130. doi:10.1159/000091712. PMID 16651823.
Mondick, J.; Oo, C.; Patel, D.; Fujitani, T.; Shimizu, K.; Barrett, J. (2009). "Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan". American Journal of Therapeutics. 16 (2): 106–115. doi:10.1097/MJT.0b013e31816b8c85. PMID 19300037.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Kamei, K.; Maeda, N.; Nomura, K.; Shibata, M.; Katsuragi-Ogino, R.; Koyama, M.; Nakajima, M.; Inoue, T.; Ohno, T.; Tatsuoka, T. (2006). "Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan". Bioorganic & Medicinal Chemistry. 14 (6): 1978–1992. doi:10.1016/j.bmc.2005.10.046. PMID 16290165.

[2] Ferro, J.; Dávalos, A. (2006). "Other neuroprotective therapies on trial in acute stroke". Cerebrovascular diseases (Basel, Switzerland). 21 Suppl 2 (2): 127–130. doi:10.1159/000091712. PMID 16651823.

[3] Mondick, J.; Oo, C.; Patel, D.; Fujitani, T.; Shimizu, K.; Barrett, J. (2009). "Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan". American Journal of Therapeutics. 16 (2): 106–115. doi:10.1097/MJT.0b013e31816b8c85. PMID 19300037.

Piclozotan

See also

References